a professor at UCL, stated that these results are significant because they provide evidence that Tecentriq can be a viable treatment option for NSCLC patients who cannot tolerate platinum-based chemotherapy.
Tecentriq is an immune checkpoint inhibitor that works by blocking the PD-L1 protein on cancer cells, allowing the body's immune system to recognize and attack the tumor. It has already been approved for the treatment of various cancers, including NSCLC, bladder cancer, and triple-negative breast cancer.
The IPSOS trial included 713 patients with advanced NSCLC who were ineligible for platinum-based doublet chemotherapy due to factors such as poor kidney function or other medical conditions. The patients were randomly assigned to receive either Tecentriq or standard single-agent chemotherapy.
The results of this trial are promising for NSCLC patients who do not have the option of undergoing platinum-based chemotherapy. Platinum-based doublet chemotherapy is often considered the standard of care for advanced NSCLC, but it can be toxic and cause significant side effects. Being able to offer an effective alternative like Tecentriq could greatly improve outcomes and quality of life for these patients.
Dr. Marina Chiara Garassino, a co-author of the study from Fondazione IRCCS Istituto Naz